PWMG
RNA icon

Private Wealth Management Group’s Atrium Therapeutics RNA Stock Holding History

Private Wealth Management Group’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-75
Closed -$1.01K – 1584
2026
Q2 		$1.01K Buy
+75
New +$980 ﹤0.01% 1305

Other funds holding RNA

Trium Capital
Trium Capital London, United Kingdom $79.4M AUM 36.67% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FNY Investment Advisers
FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return
Essential Partners
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
True Wealth Design
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
Fortitude Family Office
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

Private Wealth Management Group's RNA Position: Q3 2026 in Review

Private Wealth Management Group sold out of Atrium Therapeutics (RNA) in Q3 2026, closing a stake of 75 shares — an estimated $1.01K sold.

Private Wealth Management Group first reported a position in RNA in Q2 2026 and held it in 1 quarter. The position peaked at $1.01K in Q2 2026. 12 funds tracked by Wall St. Rank hold RNA as of Q3 2026.

  • Private Wealth Management Group reported no remaining Atrium Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Private Wealth Management Group sold 75 Atrium Therapeutics shares in Q3 2026, an estimated $1.01K.
  • Private Wealth Management Group first reported a position in Atrium Therapeutics in Q2 2026 and held it in 1 quarter.
  • Private Wealth Management Group's Atrium Therapeutics position peaked at $1.01K in Q2 2026.
  • 12 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q3 2026.

Based on Private Wealth Management Group's 13F filing for Q3 2026, filed 19 Oct 2026.